TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* advanced cancer patients (defined as locally recurrent or metastatic) over 18 years old with a decreased food intake for at least 2 weeks (reported by physician or subject)~* able to complete questionnaires in English~* able to provide informed consent~* life expectancy of greater than 2 months (as determined by physician)~* chemosensory complaint score \> 1~Exclusion Criteria:~* receiving enteral or parenteral feedings~* allergies or sensitivity to THC and/or sesame seed oil~* history of substance abuse or psychotic episodes~* mechanical obstruction of alimentary tract, mouth or nose~* received chemotherapy in the last 2 weeks~* received radiation therapy to the head/neck area~* brain tumor~* nausea score greater than 5 on ESAS~* history of tachyarrhythmias, angina pectoris or hypertension~* current diagnosis of liver impairment~* use of marijuana within 30 days prior to start of trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3561774 in Participants With Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have fasting triglycerides (TGs) within the range of 150 (1.69 millimole/liter (mmoL) to 499 milligram/deciliter (mg/dL) 2.26 to 5.64 millimole/liter (mmol/L) at screening.~* Have fasting LDL-C ≥70 mg/dL (1.81 mmol/L) at screening.~* Have non-HDL-C ≥ 130 mg/dL (3.36 mmol/L) at screening.~* Must be on a stable moderate or high-intensity dose of a statin for at least 2 months before screening and remain on the same medication and dose for the duration of the study.~* Have a body mass index within the range of 18.5 to 40.0 kilogram/square meter (kg/m²), inclusive~Exclusion Criteria:~* Have in the 6 months prior to screening, uncontrolled Type 1 or Type 2 diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization, or have an hemoglobin A1c (HbA1c) ≥8% at screening.~* Have a history of nephrotic syndrome.~* Have a history of acute or chronic pancreatitis.~* Have had within the past 3 months prior to screening~  * Myocardial infarction~ * Unstable angina~ * Coronary artery bypass graft~ * Percutaneous coronary intervention - diagnostic angiograms are permitted~ * Peripheral artery disease~ * Transient ischemic attack, or~ * Cerebrovascular accident~* Have New York Heart Association Class III or IV heart failure or last known left ventricular ejection fraction \<30%.~* Have undergone LDL apheresis within 12 months prior to screening.~* Have clinically relevant anemia, as defined by the investigator.~* Have, within 1 year prior to screening or plan on having during the study, surgical treatment for obesity.~* Have within 3 years prior to screening a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse.~* Have uncontrolled hypertension.~* Have used or are taking products for the purpose of lowering lipid levels (except for statins, PCSK9 inhibitors, bempedoic acid, and ezetimibe). This includes lipid-regulating medication, over-the-counter products, or herbal therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3561774 Dose 1 (Type: EXPERIMENTAL): Participants will receive LY3561774 subcutaneously (SC)
- LY3561774 Dose 2 (Type: EXPERIMENTAL): Participants will receive LY3561774 SC
- LY3561774 Dose 3 (Type: EXPERIMENTAL): Participants will receive LY3561774 SC
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 9th grade student at a participating high school in East or South Los Angeles~* Written parent/guardian consent and student assent to participate~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- SEI Classroom Curriculum (Type: EXPERIMENTAL): Participants receive the SEI classroom curriculum.
- Control Classroom Curriculum (Type: ACTIVE_COMPARATOR): Participants receive the control classroom curriculum.
- SEI Curriculum + 3 School Components (Type: EXPERIMENTAL): Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
- Control Curriculum + 1 School Component (Type: ACTIVE_COMPARATOR): Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing cardiac catheterization (CC) and/or percutaneous coronary intervention (PCI) via the radial artery as part of their standard of care treatment~2. Patients able and willing to give written informed consent~3. Patient \> 18 years of age~Exclusion Criteria:~1. Patients presenting with acute ST-segment elevation myocardial infarction (STEMI)~2. Oral anticoagulation therapy as described below:~   1. If on a DOAC (direct-acting oral anticoagulants - ie dabigatran, rivaroxaban, apixaban, edoxaban), patients will be excluded if DOAC taken within 48 hours and eGFR \> 30 ml/min or DOAC taken within 72 hours and eGFR \< 30 ml/min.~  2. If the patient is on warfarin, excluded if INR \> 1.5~3. Liver Failure~4. Life-threatening illness that the patient would not be expected to live more than 6 months post-procedure~5. Major unanticipated event in the cardiac cath lab (i.e. cardiac arrest) of an already consented patient, but before randomization, where the operator believes participation in this trial is now inappropriate.~6. Thrombocytopenia, with a platelet count of \< 75,000.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: NO_INTERVENTION): TR Band inflated with 10 mL of air, followed by gradual weaning over the subsequent 60 minutes.
- Arm 2 (Type: EXPERIMENTAL): QC pad with a Coban bandage to hold the pad in place to achieve hemostasis.
- Arm 3 (Type: EXPERIMENTAL): QC pad with a Tegaderm dressing to hold the pad in place to achieve hemostasis.
- Arm 4 (Type: EXPERIMENTAL): QC pad with a TR Band to hold the pad in place to achieve hemostasis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed, CD30-positive mature T-cell lymphomas~* Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~Exclusion Criteria:~* History of another primary invasive malignancy that has not been in remission for at least 3 years~* Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides~* History of progressive multifocal leukoencephalopathy (PML)~* Cerebral/meningeal disease related to the underlying malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHOP (Type: ACTIVE_COMPARATOR): cyclophosphamide, doxorubicin, vincristine, and prednisone
- A+CHP (Type: EXPERIMENTAL): brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Symptoms of OAB for at least six months prior to randomization~  * ≥ 8 micturitions on average/24 hours~ * ≥ 1 urgency episodes on average/24 hours~ * with or without UUIE~    * Patients dissatisfied with prior oxybutynin ER or tolterodine ER treatment. Patients must have been on either treatment for at least 1 week and up to 12 months preceding this study. It is required that either oxybutynin ER or tolterodine ER was the most recent OAB medication taken.~   * Patients without prior darifenacin treatment~Exclusion Criteria:~* • A mean daily urinary volume \>3000 mL or a mean volume voided/micturition of \>300 mL as verified in the micturition diary for two consecutive days prior to Baseline~  * Males with post-void residual (PVR) urinary volume \>200 mL at Baseline~ * Clinically predominant and bothersome stress urinary incontinence, as determined by the investigator~ * Urinary retention or clinically significant bladder outlet obstruction as determined by the investigator~Other protocol-defined inclusion / exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Darifenacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrent or relapsing CDI defined as EITHER(13):~  * At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g. rifaximin, nitazoxanide).~ * At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.~* Willingness to accept risk of unrelated donor stool~* Willingness to be randomized to NGT vs. colonoscopic delivery.~* Able to consent for self, or parental assent/child assent as age appropriate.~Exclusion Criteria:~* Anatomic contraindication to NGT~* Delayed gastric emptying syndrome~* Known chronic aspiration~* Contraindication to colonoscopy (ASA 4 or more)~* High risk of bacterial translocation (Immunosuppression, cirrhosis etc)~* Pregnant or breastfeeding women~* Acute unrelated infection or comorbid illness exaccerbation

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Colonoscopy (Type: EXPERIMENTAL): Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy
- Nasogastric Tube (NGT) (Type: EXPERIMENTAL): Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise healthy females with a history of primary dysmenorrhea~* Using effective birth control excluding intrauterine contraceptive device (IUCD)~* Must be 18 years of age or older~* Must give written informed consent to participate in this study~Exclusion Criteria:~* Patients with an intrauterine contraceptive device or using oral contraceptives within 3 months of treatment in this study~* Patients with confirmed pelvic inflammatory disease, endometriosis or adenomyosis~* Patients who are pregnant or who test positive at baseline or are at risk of becoming pregnant while on study~* Patients who are breastfeeding~* Patients with hepatic or renal function tests greater than the upper limit of normal and deemed clinically significant by the Investigator at screening~* Patients with a clinically significant medical or psychiatric disorder or a serious medical conditions within the past 6 months which in the opinion of the investigator, should prohibit participation in this study~* Patients who have been exposure to any investigational drug within 4 weeks prior to screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PDC31 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be scheduled to have 2 or more third molars removed, at least 1 of which is partially embedded in bone and is impacted in the lower jaw~* Patients must be experiencing moderate to severe pain following the dental procedure~Exclusion Criteria:~* Previous molar extraction within the past 45 days~* Personal or family history of an inherited bleeding disorder~* Uncontrolled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): etoricoxib 90 mg
- 2 (Type: EXPERIMENTAL): etoricoxib 120 mg
- 3 (Type: ACTIVE_COMPARATOR): ibuprofen 2400 mg
- 4 (Type: ACTIVE_COMPARATOR): acetaminophen 2400 mg/codeine 240 mg
- 5 (Type: PLACEBO_COMPARATOR): Matching Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 55 years of age~* Focal articular cartilage lesion on the medial femoral condyle~* Grade 3 or 4 acute (traumatic) or chronic (degenerative) lesion~* Stable knee~Exclusion Criteria:~* Multiple lesions or kissing lesions~* Clinically relevant compartment malalignment (\> 5 degrees)~* Undergone ligament treatments in the affected knee within 2 years prior to trial~* Inflammatory arthropathy, such as rheumatoid arthritis, systemic lupus, or active gout~* Previous surgical cartilage treatments in the affected knee in the last 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Microfracture with BST-CarGel (Type: EXPERIMENTAL): BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
- Microfracture without BST-CarGel (Type: ACTIVE_COMPARATOR): Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, aged ≥ 18 years and ≤ 45 years.~* Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS.~* External genital endometriosis confirmed by laparoscopy.~* Existing pelvic (vaginal) ultrasound data not earlier than 2 months before inclusion in the study.~* Prescribed treatment with Duphaston® according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle or continuously.~* No hormonal treatment in 2 cycles before enrollment.~* Signed Patient Authorization for Use/Disclosure of Data.~Exclusion Criteria:~* Any co-existing disease(s) needing chronic drug therapy (e.g. Crohn's disease, diabetes etc); Severe concomitant medical illness.~* Severe other genital pathology excluding endometriosis (e.g. Multiple/severe myoma; adenomyosis, inflammatory diseases, etc.).~* Routine consumption of analgesics other than for the pain of endometriosis.~* Patients receiving hormonal contraceptives in last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives etc.).~* Ongoing pregnancy.~* Menopause or premature ovarian failure.~* Contraindications to dydrogesterone treatment listed in the locally approved label (Instructions for the medical use of Duphaston®).~* Any other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions and special warnings listed in the locally approved label (Instructions for the medical use of Duphaston®).~* Abnormal results of pap smear test.~* Other conditions that made the patients participation impossible (based on the investigator decision).~* Fertility treatments using assisted reproductive technology.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Endometriosis/Dydrogesterone (Type: None): Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~For healed reflux esophagitis study~* Endoscopically verified reflux esophagitis, Grade A or higher according to the Los Angels classification as judged by central evaluation committee.~For prevention of gastric ulcer or duodenal ulcer recurrence study~* Patients with documented medical history of gastric ulser or duodenal ulser diagnosis based on upper gastrointestinal symptoms, fecal occult blood, esophagogastroduodenoscopy findings, etc.~Exclusion Criteria:~* Patients less than 10 kg in weight.~* Use of any other investigational compounds or participations in another clinical trial within 4 weeks prior to the enrolment.~* Significant clinical illness within 4 weeks prior to the informed consent~* Previous total gastrectomy.~* Presence of hepatic diseases or other conditions that could interfere with evaluation of the study as judged by investigators. etc.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Group1 (Type: EXPERIMENTAL): Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
- Group2 (Type: EXPERIMENTAL): Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
- Group3 (Type: EXPERIMENTAL): D961H 10 mg once-daily (32 or 52 weeks)
- Group4 (Type: EXPERIMENTAL): D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete